Please login to the form below
evidence
This page shows the latest evidence news and features for those working in and with pharma, biotech and healthcare.
Biotech leaders jump into US free speech debate
However, they add: “We see no compelling evidence to indicate that this is more prevalent now than it was 250 years ago at the time of our country’s founding, or
Latest news
-
Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
NICE says the committee will consider comments received on the draft guidance, together with any new evidence, at its next meeting on 23 October 2018.
-
Tox trouble stalls Sosei/Allergan Alzheimer’s drug
It has already completed another phase 1 study and – according to the partners – has been well-tolerated with no evidence of cancer in around 310 patients treated to date.
-
FDA rejects GSK’s Nucala for COPD
FDA rejects GSK’ s Nucala for COPD. Says evidence that Nucala was effective in preventing COPD exacerbations was insufficient. ... the agency reviewers who suggested that GSK had failed to provide sufficient evidence that Nucala was effective in
-
FDA rejects GSK’s Nucala for COPD
the agency reviewers who suggested that GSK had failed to provide sufficient evidence that Nucala was effective in preventing COPD exacerbations.
-
Sangamo’s first gene-editing trial doesn’t convince investors
Investors and analysts seemed to be spooked by Sangamo’s inability to show that its one-off therapy was actually causing an increase in IDS levels, which would provide evidence that
More from news
Approximately 12 fully matching, plus 1,068 partially matching documents found.
Latest Intelligence
-
The European Medicines Agency: PRIME’d for access?
That could help to overcome issues with the evidence that payers want to see.
-
Trust me, I’m from pharma
For example, a major multinational has developed an evidence-based treatment algorithm that’s helping UK GPs define and manage the treatment paradigm for every part of the diabetes pathway. ... When the evidence-base is there, pharma should not shy
-
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?
Considerable effort was directed towards medicines optimisation and building an evidence base for the wider use of NOACs in appropriate patients.
-
What can pharma learn from the charity sector?
Initiatives such as the Information Standard, run by NHS England, give charities guidance and standards to adhere to when communicating health information, ensuring that it is evidence-based, clear and easy
-
The rise of vertical integration in the US payer landscape
PBM-medical management company merger: ESI/eviCore Healthcare. A traditional PBM, ESI announced it was purchasing eviCore Healthcare, a privately held company offering health plans and other risk-bearing, evidence-based ... Engaging in a decision support
More from intelligence
Approximately 8 fully matching, plus 246 partially matching documents found.
Latest appointments
-
Open Access Consulting appoints new director
evidence. Commenting on the appointment, Dorinda Hickey, CEO of Open Access Consulting, said: “We are delighted to have Jayne on board.
-
Claes Buxfeldt joins NDA
He has represented the payer voice in development programmes including the development of payer evidence strategies, pricing, market access strategy, economic models and clinical programme input.
-
Remi Gauchoux joins Carenity
Gauchoux has a 20-year international experience in healthcare and the CRO industries with expertise in late phase and real-world evidence analysis.
-
McCann Health appoints Daniel Carucci as global medical director
His in-depth understanding of the scientific method and practical rationale will enable McCann Health to more effectively close the critical evidence-to-practice gap and give greater purpose to science
-
Ashfield appoints new leaders in the US and Japan
We’ll continue to excel by providing flexible, evidence-based services and I look forward to working with new clients and brand challenges in Japan.”.
More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest from PMHub
-
More tell, less sell: HCP-centric comms
Perhaps as a result, the evidence[7] now shows that doctors have distanced themselves from the pharma rep, with some going as far as to not entertain them at all, whether ... With respect to the tradition of ‘ detailing’, evidence suggests that HCPs
-
Drive payer submission readiness for your Phase 2 and 3 products
Presents a comprehensive summary of the evidence gaps with a red-amber-green rating of potential challenges, encouraging early clear and consistent communication across the organization. ... Accelerates HTA submission readiness by producing a
-
PRMA Consulting Ltd
Our tailored services include strategic market access, landscape assessments, payer and KOL engagement, value propositions, GVDs, evidence generation, real-world evidence, pricing and reimbursement strategy.
-
Mastering the precision medicine opportunity
The 4ps of Precision Medicine. The National Cancer Institute and the Centre for Disease Control both use the 4Ps model to define precision medicine, considering it a form of evidence-based
-
How can pharma engage with key stakeholders on NHS service transformation?
reconfiguration, states that clinical engagement and approval, and strong clinical evidence are key. ... Assurance for NHS management within this paper means: is there documented evidence that the transformation process has looked at clinical best
More from PMHub
Approximately 5 fully matching, plus 225 partially matching documents found.
Featured jobs
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Account Manager
-
Negotiable
-
Systematic Review Lead- London
-
Negotiable
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Medical Writers Required - Hertfordshire
-
Competitive
-
Sudler London - Account Director
-
Competitive
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
-
Senior Medical Writer
-
Salary is DOE
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Sudler London - Senior Medical Writer
-
Competitive
- Account Director or Senior Account Director
-
Salary TBC
Subscribe to our email news alerts
- Lucid limbers up for second annual sports day
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- Hanover Health launches award, Firstlight spins off healthcare arm and more
- J&J files ‘breakthrough’ bladder cancer drug in US
- Boehringer’s Corsico to be new GSK drug dev leader
- More tell, less sell: HCP-centric comms
PMHub
Real Science Communications
Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
